KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Free Cash Flow (2018 - 2025)

Vir Biotechnology's Free Cash Flow history spans 8 years, with the latest figure at -$26.2 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 70.74% year-over-year to -$26.2 million; the TTM value through Dec 2025 reached -$396.6 million, up 12.57%, while the annual FY2025 figure was -$396.6 million, 12.57% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$26.2 million at Vir Biotechnology, up from -$167.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $939.5 million in Q2 2022 and bottomed at -$398.7 million in Q2 2023.
  • The 5-year median for Free Cash Flow is -$89.8 million (2021), against an average of -$6.2 million.
  • The largest annual shift saw Free Cash Flow skyrocketed 1249.16% in 2021 before it tumbled 585.38% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$9.9 million in 2021, then surged by 327.09% to $22.6 million in 2022, then crashed by 585.38% to -$109.5 million in 2023, then rose by 18.12% to -$89.6 million in 2024, then skyrocketed by 70.74% to -$26.2 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Free Cash Flow are -$26.2 million (Q4 2025), -$167.9 million (Q3 2025), and -$122.8 million (Q2 2025).